Drug Information

Drug (ID: DG01170) and It's Reported Resistant Information

• Name: Delamanid
• Synonyms: Delamanid; 681492-22-8; OPC-67683; Delamanid (OPC-67683); UNII-8OOT6M1PC7; OPC 67683; (R)-2-Methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)phenoxy)methyl)-2,3-dihydroimidazo[2,1-b]oxazole; 8OOT6M1PC7; MMV688262; (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole; (2R)-2,3-Dihydro-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]phenoxy]methyl]imidazo[2,1-b]oxazole; (2R)-2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole; (R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole; (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidyl]phenoxy]methyl]-3H-imidazo[2,1-b]oxazole; (R)-2-methyl-6-nitro-2-(4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole; Deltyba (TN); Delamanid (JAN/USAN); OPC-67683; Delamanid; SCHEMBL57791; Delamanid [USAN:INN:JAN]; CHEMBL218650; DTXSID60218326; CHEBI:134742; BCP07838; EX-A2414; MFCD18251539; NSC794689; s5007; ZINC43100810; AKOS025289781; CCG-269934; CS-5866; DB11637; NSC-794689; SB14863; NCGC00348214-01; (2R)-2-Methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1- yl)phenoxy)methyl)-2,3-dihydroimidazo(2,1-b)oxazole; AS-56105; Delamanid; OPC 67683; OPC67683; HY-10846; Imidazo(2,1-b)oxazole, 2,3-dihydro-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)-1-piperidinyl)phenoxy)methyl)-, (2R)-; D09785; A856044; Q15408413; (2R)-2-Methyl-6-nitro-2-[4-[4-[4-(trifluoromethoxy)phenoxy]piperidino]phenoxymethyl]-2,3-dihydroimidazo[2,1-b]oxazole; [(2R)-2-methyl-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidyl]phenoxy]methyl]-3H-imidazo[2,1-b]oxazol-6-yl]azinic acid; 2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b]oxazole, (2R)-
• Indication:
  In total 2 Indication(s)
  Multi-drug resistant tuberculosis [ICD-11: MG50-MG52]; Approved; [1]
  Mycobacterium infection [ICD-11: 1B10-1B21]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Mycobacterial diseases [ICD-11: 1B2Z ]; [1]
• Target: Bacterial Cell membrane (Bact CM); NOUNIPROTAC; [1]
• Formula: C25H25F3N4O6
• IsoSMILES: C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F
• InChI: 1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1
• InChIKey: XDAOLTSRNUSPPH-XMMPIXPASA-N
• PubChem CID: 6480466
• ChEBI ID: CHEBI:134742
• TTD Drug ID: D0S3NU
• INTEDE ID: DR0432

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Mycobacterial diseases [ICD-11: 1B2Z ]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: FO synthase (FBIC) [1]

• Molecule Alteration: Missense mutation; p.V318I
• Resistant Disease: Mycolicibacterium smegmatis infection [ICD-11: 1B2Z.6]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Streptococcus pneumoniae strain; 1313
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: alamarBlue assay
• Mechanism Description: Mutation in codon 318 of the fbiC gene was identified as the sole mutation related to DMD resistance.

References

• Ref 1: In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China .Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00900-17. doi: 10.1128/AAC.00900-17. Print 2017 Oct. 10.1128/AAC.00900-17